About: A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 April 1991

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у квітні 1991 (uk) article scientifique publié en 1991 (fr) im April 1991 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'abril de 1991 (ast) scientific article published on 01 April 1991 (en)
publication date	wds:Q70131429-8F53246E-B8D3-4A20-AA4F-C752573B54F9
publication date	1991-04-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q70131429-F903A525-F0FD-444A-B267-13BCBA94B9AA
language of work or name	English
author name string	wds:Q70131429-25DE2096-8CBD-4DD9-95A9-2B6E6E4E2D7B wds:Q70131429-4A3ABED7-6A7A-4809-9367-4C810BC27D7E wds:Q70131429-515780FA-E6B6-412F-AAE7-0093D22E48BE wds:Q70131429-59D5CC51-FC0E-48BB-8386-6F156F05BC77 wds:Q70131429-797E0019-5C7A-40A0-98FE-9D21172FC625 wds:Q70131429-A7821C0E-1862-4504-A3C8-0AEBB8BAD065 wds:Q70131429-B78DB85F-B758-4EF8-A506-82AF2471B4CE wds:Q70131429-B7C3C51B-E54E-40C1-B8D9-2018E5031A6B wds:Q70131429-7C58F5ED-6703-4AF7-BADB-6C01A2532C3E wds:Q70131429-DD5C6775-35B1-414E-AEF0-FFCFF543D133
author name string	A Miller W Weiss M Weitzman S Appel M B Bornstein S Slagle E Drexler V Spada L Rolak M Keilson
rdfs:label	A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis (en) A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis (nl)
skos:prefLabel	A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis (en) A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis (nl)
name	A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis (en) A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis (nl)
title	wds:Q70131429-D3EC805A-F869-419C-889A-C3C767D1CBF6
title	A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis (en)
page(s)	wds:Q70131429-960800D1-E312-4E3A-B652-3C33E42FF704
page(s)	533-539
instance of	wds:Q70131429-15B46600-4B1E-4203-8004-90E5D4D983A7
instance of	scholarly article
main subject	wds:Q70131429-2AFD6CB4-0F0B-472C-902F-B45B0AF9E222 wds:Q70131429-4D93C850-8009-4754-BD23-17E342EDEE68 wds:Q70131429-6859CDFE-2253-4052-A68A-2765FECBBDBF
main subject	placebo multiple sclerosis chronic progressive multiple sclerosis
PubMed ID	wds:Q70131429-819302C1-BB93-4E36-BB40-42E899DF5E4C
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/2011253
PubMed ID	2011253
published in	wds:Q70131429-A69507C9-44FE-4061-BA3B-955E6737419D
published in	Neurology
issue	wds:Q70131429-A627A9E7-D43F-4BB3-B24C-A3865FC0567B
volume	wds:Q70131429-905A0DE1-D79B-44E7-A42D-9BB77EE0102D
issue	4
volume	41
DOI	wds:Q70131429-917A4F40-D1DA-4267-B804-9E99C6C241F2
DOI	http://dx.doi.org/10.1212/WNL.41.4.533
DOI	10.1212/WNL.41.4.533
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q70131429
is cites work of	Natural history of multiple sclerosis Therapy with glatiramer acetate for multiple sclerosis Lack of evidence for use of glatiramer acetate in multiple sclerosis Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines Glatiramer acetate for multiple sclerosis The dynamics of multiple sclerosis. The Charcot Lecture. Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel. Primary progressive multiple sclerosis: increasing clarity but many unanswered questions Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis Therapeutic strategies in multiple sclerosis. I. Immunotherapy The natural history of multiple sclerosis Contribution of relapses to disability in multiple sclerosis Risk-benefit assessment of glatiramer acetate in multiple sclerosis Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives Copolymer 1 inhibits experimental autoimmune uveoretinitis Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis Disease-modifying Therapies for Multiple Sclerosis. Glatiramer acetate (Copaxone®) therapy for multiple sclerosis Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis Interferon beta and glatiramer acetate therapy Intrathecal methotrexate treatment in multiple sclerosis Total lymphoid irradiation in multiple sclerosis Management of secondary-progressive multiple sclerosis Treatment of multiple sclerosis A review of the clinical efficacy profile of copolymer 1: new U.S. phase III trial data Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary progressive multiple sclerosis Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis Treatment of multiple sclerosis with IVIg: potential effects and methodology of clinical trials Placebo? no thanks, it might be bad for me! Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis Immunological Aspects of Approved MS Therapeutics Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1) Medications used in the treatment of multiple sclerosis. Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review Does a placebo-effect exist in clinical trials on multiple sclerosis? Review of the literature Update on multiple sclerosis therapy.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software